摘要
In the current treatment of type 2 diabetes, exogenous GLP-1 analogues have limitations such as passive administration, non-physiological pulse release, and dose fixation, making it difficult to achieve glucose-dependent intelligent regulation. Synthetic biology provides a new strategy: engineered bacteria colonizing the intestine are transformed into "living endocrine cells", and their glucose concentration-dependent responses are used to achieve closed-loop therapy.In this paper, the molecular basis and regulatory prospects of this technology are systematically expounded. Firstly, bacteria are endowed with precise glucose-sensing ability through prokaryotic two-component systems, eukaryotic GPCR heterologous reconstitution, or ribose switches. Secondly, gene circuits including promoter switches, negative feedback memory modules, and quorum sensing are designed to convert chemical signals into efficient secretion of GLP-1, and optimize secretion pathways and intestinal colonization adaptation. Furthermore, the homeostatic regulatory mechanisms, such as multi-nutrient sensing integration, microenvironment remodeling, and immunocompatibility, are discussed to realize the multi-dimensional dialogue between engineered bacteria and hosts. Finally, the challenges of sensor sensitivity, gene drift, and clinical translation are analyzed, and future directions such as gut-brain axis intervention, living bioelectronics, and multiple therapeutic modules are prospected.The transformation of intestinal bacteria into endogenous glucose receptors is essentially the functional enhancement and digital reconstruction of the body's native endocrine system, marking the inevitable trend of metabolic disease treatment from "stoichiometry" to "biointelligent computing".